HEMOGENYX PHARMACEUTICALS PLC Financials Hemogenyx Pharmaceuticals Plc
Equities
SILF
GB00BYX3WZ24
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.567 GBX | +0.13% |
|
-3.81% | -31.87% |
| 04-25 | EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout | AN |
| 04-25 | Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 8.901 | 7.564 | 7.044 | 41.85 | 18.37 | 12.98 |
| Enterprise Value (EV) 1 | 7.024 | 6.974 | 7.803 | 41.66 | 11.54 | 13.87 |
| P/E ratio | -2.76 x | -5.12 x | -4.85 x | -19.2 x | -2.85 x | -3.26 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -8.39 x | -4.46 x | -4.79 x | -20 x | -4.42 x | -3.55 x |
| EV / FCF | -34 x | -8.13 x | -9.09 x | -37.9 x | -3.72 x | -5.79 x |
| FCF Yield | -2.94% | -12.3% | -11% | -2.64% | -26.9% | -17.3% |
| Price to Book | 4.22 x | 7.89 x | -20.3 x | 47 x | 2.24 x | 3.96 x |
| Nbr of stocks (in thousands) | 356,043 | 360,176 | 361,243 | 433,636 | 979,749 | 979,749 |
| Reference price 2 | 0.0250 | 0.0210 | 0.0195 | 0.0965 | 0.0188 | 0.0132 |
| Announcement Date | 13/06/18 | 28/05/19 | 13/05/20 | 28/05/21 | 08/06/22 | 02/06/23 |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -0.8371 | -1.563 | -1.627 | -2.081 | -2.613 | -3.908 |
| EBIT 1 | -0.8707 | -1.615 | -1.684 | -2.15 | -2.703 | -3.998 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -2.411 | -1.521 | -1.488 | -2.095 | -5.108 | -3.987 |
| Net income 1 | -2.362 | -1.478 | -1.451 | -2.082 | -5.099 | -3.979 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.009073 | -0.004102 | -0.004021 | -0.005019 | -0.006588 | -0.004061 |
| Free Cash Flow 1 | -0.2068 | -0.8577 | -0.8581 | -1.098 | -3.106 | -2.395 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 13/06/18 | 28/05/19 | 13/05/20 | 28/05/21 | 08/06/22 | 02/06/23 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 0.76 | - | - | 0.89 |
| Net Cash position 1 | 1.88 | 0.59 | - | 0.18 | 6.83 | - |
| Leverage (Debt/EBITDA) | - | - | -0.4661 x | - | - | -0.2278 x |
| Free Cash Flow 1 | -0.21 | -0.86 | -0.86 | -1.1 | -3.11 | -2.39 |
| ROE (net income / shareholders' equity) | -187% | -95.6% | -476% | -796% | -113% | -69.9% |
| ROA (Net income/ Total Assets) | -35.1% | -43% | -62.9% | -72.4% | -30.2% | -32% |
| Assets 1 | 6.731 | 3.436 | 2.308 | 2.877 | 16.88 | 12.43 |
| Book Value Per Share 2 | 0.0100 | 0 | -0 | 0 | 0.0100 | 0 |
| Cash Flow per Share 2 | 0.0100 | 0 | 0 | 0 | 0.0100 | 0 |
| Capex 1 | 0.06 | 0.02 | 0.01 | 0.17 | 0.64 | 0.43 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 13/06/18 | 28/05/19 | 13/05/20 | 28/05/21 | 08/06/22 | 02/06/23 |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -31.87% | 26.23M | |
| -1.65% | 104B | |
| +6.75% | 97.47B | |
| +5.71% | 22.25B | |
| -12.60% | 21.68B | |
| -9.70% | 18.2B | |
| -39.98% | 17.02B | |
| -10.17% | 16.36B | |
| +6.12% | 14.39B | |
| +35.47% | 12.37B |
- Stock Market
- Equities
- SILF Stock
- Financials Hemogenyx Pharmaceuticals Plc
